CNS 서비스
생명유지 필수기관인 중추 신경계(CNS, Central Nerve System)와 연관된 다양한 target들로 구성된 panel이며, 이를 통해 개발중인 약물의 MOA 및 off-target effect를 확인할 수 있습니다.
| Eurofins DiscoverX(Eurofins Discovery) 공식 대리점
Li Gan et al, Nature Neuroscience(2018), Converging Pathways in neurodegeneration, from genetics to mechanisms
서비스 종류 및 샘플 준비 방법
| 서비스 유형 | CNS Target Panel | SafetyScreen CNS panel | Drug Abuse Safety Panel | Drug Abuse Potential Panel |
| Item No. | PP280 | P411 | PP279 | P293 |
| Assay 수 | 94 | 99 | 48 | 44 |
| Sample Volume | 150 μl of 10 mM stock | 230 μl of 10 mM stock | 150 μl of 10 mM stock | 105 μl of 10 mM stock |
| 반복횟수 | Duplicate | Duplicate | Duplicate | Duplicate |
| TAT | 10 Days | 15 Days | 10 Days | 15 Days |
| 서비스 장소 | Panlabs, Taiwan | Cerep, France | Panlabs, Taiwan | Cerep, France |
| 서비스 유형 | Pain Target Panel* | Alzheimer’s MoA Panel | Parkinson’s MoA Panel | Neurodegeneration Phenotypic Panel |
| Item No. | PP293 | PP284 | PP285 | PP283 |
| Assay 수 | 44 | 41 | 27 | 3 |
| Sample Volume | 1 농도:150 μl of 10 mM stock Dose response: 275 of 10mM stock |
120 μl of 10 mM stock | 120 μl of 10 mM stock | 240 μl of 10 mM stock |
| 반복횟수 | Duplicate | Duplicate | Duplicate | 8 concentration, Duplicate |
| TAT | 10 Days | 10 Days | 10 Days | 30 Days |
| 서비스 장소 | Panlabs, Taiwan | Panlabs, Taiwan | Panlabs, Taiwan | Panlabs, Taiwan |
* Pain Target Panel
Pain(통증) 인식과 연관된 Molecular Target들로 구성된 Panel입니다.
서비스 상세
CNS Target Panel / SafetyScreen CNS Panel
중추 신경계(CNS, Central Nerve System)와 연관된 다양한 target들로 구성된 panel입니다.
2종류의 Panel(CNS Target-대만/SafetyScreen CNS-프랑스)이 있으며, SafetyScreen CNS에서 5개의 Assay(연두색 표시)가 더 포함되어 있습니다.
| Enzyme | GPCR | Ion Channel | |
| ATPase (Na+/K+), Brain, Pig | Adenosine A1 | Dopamine D3 | Calcium Channel L-Type, Benzothiazepine |
| Carbonic Anhydrase II | Adenosine A2A | Dopamine D4.4 | Calcium Channel L-Type, Dihydropyridine |
| Catechol-O-Methyl Transferase (COMT) | Adenosine A2B | Endothelin ETA | Calcium Channel L-Type, Phenylalkylamine |
| Cholinesterase, Acetyl, ACES | Adenosine A3 | Glutamate, Metabotropic, mGlu5 | Calcium Channel N-Type |
| CYP450, 1A2 | Adrenergic alpha1A | Melatonin MT1 | GABAA, Chloride Channel, TBOB |
| CYP450, 2C19 | Adrenergic alpha1B | Muscarinic M1 | GABAA, Flunitrazepam, Central |
| CYP450, 2D6 | Adrenergic alpha2A | Muscarinic M2 | GABAA (alpha1/beta2/gamma2) |
| CYP450, 3A4 | Adrenergic alpha2B | Muscarinic M3 | Glutamate, AMPA |
| GABA Transaminase | Adrenergic alpha2C | Muscarinic M4 | Glutamate, Kainate |
| Monoamine Oxidase MAO-A | Adrenergic beta1 | Muscarinic M5 | Glutamate, NMDA, Agonism |
| Monoamine Oxidase MAO-B | Adrenergic beta2 | Tachykinin NK1 | Glutamate, NMDA, Phencyclidine |
| Peptidase, Angiotensin Converting Enzyme | Bradykinin B2 | Neuropeptide Y Y1 | Glutamate, Glycine, Strychnine-intensive |
| Peptidase, CTSB (Cathepsin B) | Calcitonin Gene-Related Peptide CGRP1 | Neuropeptide Y Y2 | Glycine, Strychnine-Sensitive |
| Peptidase, CTSL (Cathepsin L) | Cannabinoid CB1 | Opiate delta1 (OP1, DOP) | Nicotinic Acetylcholine alpha4beta2, Cytisine |
| Phosphodiesterase PDE4D2 | Cannabinoid CB2 | Opiate kappa (OP2, KOP) | Nicotinic Acetylcholine alpha7, Bungarotoxin |
| Protein Serine/Threonine Kinase, MAPK14 (p38alpha) | Cholecystokinin CCK1 (CCKA) | Opiate mu (OP3, MOP) [3H]morphine | Potassium Channel [SKCA] |
| Protein Tyrosine Kinase, EGF Receptor | Cholecystokinin CCK2 (CCKB) | 5-HT4E Human Serotonin | Purinergic P2X |
| Protein Tyrosine Kinase, Insulin Receptor | Dopamine D1 | Orexin OX2 | Serotonin (5-Hydroxytryptamine) 5-HT3 |
| Tyrosine Hydroxylase | Dopamine D2L | Orexin OX1 | Sodium Channel, Site 2 |
| JNK1 Human CMGC Kinase Enzymatic LANCE Assay [Km ATP] | Dopamine D3 | Oxytocin | Nuclear Hormone Receptor |
| Transporter | Dopamine D4.4 | Serotonin (5-Hydroxytryptamine) 5-HT1A | Androgen (Testosterone) |
| Transporter, Adenosine | Endothelin ETA | Serotonin (5-Hydroxytryptamine) 5-HT1B | Estrogen ERalpha |
| Transporter, Norepinephrine (NET) | GABAB1B | Serotonin (5-Hydroxytryptamine) 5-HT2A | Glucocorticoid |
| Transporter, Dopamine (DAT) | Glutamate, Metabotropic, mGlu5 | Serotonin (5-Hydroxytryptamine) 5-HT2B | Others |
| Transporter, GABA | Histamine H1 | Serotonin (5-Hydroxytryptamine) 5-HT2C | BZDp (TSPO) |
| Transporter, Serotonin (5-Hydroxytryptamine) (SERT) | Histamine H3 | Serotonin (5-Hydroxytryptamine) 5-HT7 | TNF-alpha |
| Vasopressin V1A | Sigma, Non-Selective | ||
Drug Abuse Safety Panel/Drug Abuse Potential Panel
Drug Abuse(약물 남용)에 관련된 2 종류의 Panel 서비스(Drug Abuse Safety Panel-대만/Drug Abuse Potential Panel-프랑스)를 제공합니다.
2017, FDA guideline, Assessment of Abuse Potential of Drugs에 따른 Assay로 구성되어 있습니다.
| Drug Abuse Safety-48 assay | Drug Abuse Potential-44 assay | ||
| Enzyme | |||
| 104010 | Cholinesterase, Acetyl, ACES | ||
| 195010 | Tyrosine Hydroxylase | ||
| GPCR | |||
| 203110 | Adrenergic alpha1A | 2338 | Adrenergic alpha1A |
| 203210 | Adrenergic alpha1B | ||
| 203400 | Adrenergic alpha1D | ||
| 203630 | Adrenergic alpha2A | 13 | Adrenergic alpha2A |
| 203710 | Adrenergic alpha2B | 1344 | Adrenergic alpha2B |
| 203810 | Adrenergic alpha2C | 16 | Adrenergic alpha2C |
| 204010 | Adrenergic beta1 | 18 | Adrenergic beta1 |
| 204110 | Adrenergic beta2 | 20 | Adrenergic beta2 |
| 217050 | Cannabinoid CB1 | 4708 | Cannabinoid CB1 |
| 217100 | Cannabinoid CB2 | 37 | Cannabinoid CB2 |
| 219500 | Dopamine D1 | 44 | Dopamine D1 |
| 219700 | Dopamine D2S | 1322 | Dopamine D2S |
| 228610 | GABAB1A | ||
| 228710 | GABAB1B | ||
| 236400 | Glutamate, Metabotropic, mGlu2 | ||
| 252610 | Muscarinic M1 | 91 | Muscarinic M1 |
| 252710 | Muscarinic M2 | 93 | Muscarinic M2 |
| 252810 | Muscarinic M3 | 95 | Muscarinic M3 |
| 252910 | Muscarinic M4 | 96 | Muscarinic M4 |
| 253010 | Muscarinic M5 | 97 | Muscarinic M5 |
| 260130 | Opiate delta1 (OP1, DOP) | 114 | Opiate delta1 (OP1, DOP) |
| 260210 | Opiate kappa (OP2, KOP) | 4461 | Opiate kappa (OP2, KOP) |
| 260430 | Opiate mu (OP3, MOP) [3H]morphine | 118 | Opiate mu (OP3, MOP) [3H]morphine |
| 299030 | Orexin OX1 | 1987 | Orexin OX1 |
| 299002 | Orexin OX2 | 1988 | Orexin OX2 |
| 271110 | Serotonin (5-Hydroxytryptamine) 5-HT1A | 131 | Serotonin (5-Hydroxytryptamine) 5-HT1A |
| 271230 | Serotonin (5-Hydroxytryptamine) 5-HT1B | ||
| 271650 | Serotonin (5-Hydroxytryptamine) 5-HT2A | 471 | Serotonin (5-Hydroxytryptamine) 5-HT2A |
| 271700 | Serotonin (5-Hydroxytryptamine) 5-HT2B | 1333 | Serotonin (5-Hydroxytryptamine) 5-HT2B |
| 271800 | Serotonin (5-Hydroxytryptamine) 5-HT2C | 1003 | Serotonin (5-Hydroxytryptamine) 5-HT2C |
| Drug Abuse Safety-48 assay | Drug Abuse Potential-44 assay | ||
| Ion Channel | |||
| 216000 | Calcium Channel N-Type | 164 | Calcium Channel N-Type |
| 226600 | GABAA, Flunitrazepam, Central | 28 | GABAA, Flunitrazepam, Central |
| 232600 | Glutamate, AMPA | 64 | Glutamate, AMPA |
| 232710 | Glutamate, Kainate | 65 | 65 |
| 232810 | Glutamate, NMDA, Agonism | 66 | Glutamate, NMDA, Agonism |
| 233000 | Glutamate, NMDA, Phencyclidine | 124 | Glutamate, NMDA, Phencyclidine |
| 299032 | Nicotinic Acetylcholine alpha7, Bungarotoxin | 3010 | Nicotinic Acetylcholine alpha7, Bungarotoxin |
| 258660 | Nicotinic Acetylcholine alpha7, Methyllycaconitine | 170 | GABAA, TBPS |
| 271910 | Serotonin (5-Hydroxytryptamine) 5-HT3 | 411 | Serotonin (5-Hydroxytryptamine) 5-HT3 |
| 169 | Sodium Ion Channel, Batrachotoxinin(Site 2) | ||
| 3029 | nAChR (alpha4/beta2) | ||
| 3051 | GABAA (alpha1/beta2/gamma2) | ||
| 68 | Glutamate, Glycine (Strychnine-Insensitive) | ||
| Nuclear Hormone Receptor | |||
| 226010 | Estrogen ERalpha | 933 | Androgen |
| 226050 | Estrogen ERbeta | 152 | Estrogen ERbeta |
| 232030 | Glucocorticoid | 469 | Glucocorticoid |
| Transporter | |||
| 220320 | Transporter, Dopamine (DAT) | 52 | Transporter, Dopamine (DAT) |
| 226400 | Transporter, GABA | 60 | Transporter, GABA |
| 204410 | Transporter, Norepinephrine (NET) | 355 | Transporter, Norepinephrine (NET) |
| 274030 | Transporter, Serotonin (5-Hydroxytryptamine) (SERT) | 439 | Transporter, Serotonin (5-Hydroxytryptamine) (SERT) |
Neurodegeneration Phenotypic Panel
Cell based Phenotypic Panel로서, 신경 퇴행성 질환 후보 약물 처리 시, ≥ 50% increase of neurite outgrowth를 통해 효능을 확인할 수 있는 서비스입니다.
| FAMILY | NAME | ITEM NUMBER | PROTEIN NAME | ORGANISM | ASSAY SUB TYPE |
| Cell Based Phenotypic | Alpha-Synuclein A53T Parkinson’s Disease Genetic Cell Based Agonist Neurite Outgrowth Assay, Panlabs | 332400-0 | SYUA_HUMAN | Human | Cell Based |
| Cell Based Phenotypic | APOEε4 C130R Sporadic Alzheimer’s Disease Genetic Cell Based Agonist Neurite Outgrowth Assay, Panlabs | 332440-0 | APOE_HUMAN | Human | Cell Based |
| Cell Based Phenotypic | APP- PS1- MAPT Familial Alzheimer’s Disease Genetic Cell Based Agonist Neurite Outgrowth Assay, Panlabs | 332460-0 | A4_HUMAN | Human | Cell Based |
서비스 절차
서비스 문의